Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -27.16
- Piotroski Score 3.00
- Grade Hold
- Symbol (APGN)
- Company Apexigen, Inc.
- Price $0.39
- Changes Percentage (8.48%)
- Change $0.03
- Day Low $0.36
- Day High $0.40
- Year High $8.28
Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and rectal and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. The company was founded in 2010 and is based in San Carlos, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/14/2022
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.71
- Trailing P/E Ratio -0.22520467836257
- Forward P/E Ratio -0.22520467836257
- P/E Growth -0.22520467836257
- Net Income $-31,452,000
Income Statement
Quarterly
Annual
Latest News of APGN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
An Intrinsic Calculation For APG|SGA SA (VTX:APGN) Suggests It's 39% Undervalued
APG|SGA's stock may not be reflecting its true value, as competitors trade at a smaller discount. Using a two-stage DCF model, future cash flows are estimated and discounted to present value to determ...
By Yahoo! Finance | 2 weeks ago
